PROCEPT BioRobotics (NASDAQ:PRCT) Stock Price Down 4.8% – Here’s Why

PROCEPT BioRobotics Corporation (NASDAQ:PRCT)’s stock price fell 4.8% during trading on Thursday . The stock traded as low as $21.17 and last traded at $20.9120. 125,719 shares were traded during mid-day trading, a decline of 92% from the average daily volume of 1,546,816 shares. The stock had previously closed at $21.97.

PROCEPT BioRobotics News Roundup

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Negative Sentiment: The lawsuits allege that PROCEPT and certain senior executives failed to disclose inventory problems, weaker-than-expected handpiece sales and repeated late-quarter bulk discounts. Attorneys claim the discount program may have pulled demand forward, inflated recurring-revenue metrics and left customers with excess inventory. Hagens Berman securities fraud class action notice
• Negative Sentiment: Several firms are highlighting a lead-plaintiff deadline of September 22, 2026 for investors who purchased PRCT shares between February 28, 2024, and February 25, 2026. The notices reference an alleged decline of roughly 18% on inventory revelations and, in some claims, a more than 75% decline over the relevant period. The allegations have not been proven in court. SBS class action notice
• Neutral Sentiment: The numerous releases from SBS, Pomerantz, Rosen, Kaplan Fox, ClaimsFiler, Kahn Swick & Foti and other firms largely repeat the same lawsuit and deadline information rather than announce a new operating development. However, the volume of alerts keeps legal and disclosure concerns prominent for investors. Pomerantz investor alert

Wall Street Analyst Weigh In

PRCT has been the subject of a number of research reports. Jefferies Financial Group reiterated a “hold” rating and issued a $20.00 price objective on shares of PROCEPT BioRobotics in a report on Wednesday, August 5th. TD Cowen cut their target price on PROCEPT BioRobotics from $34.00 to $28.00 and set a “buy” rating on the stock in a report on Wednesday, August 5th. Piper Sandler reduced their price objective on shares of PROCEPT BioRobotics from $35.00 to $25.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 5th. William Blair cut PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 5th. Finally, Truist Financial set a $21.00 price target on shares of PROCEPT BioRobotics in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $25.09.

PROCEPT BioRobotics Stock Performance

The company has a quick ratio of 5.35, a current ratio of 6.55 and a debt-to-equity ratio of 0.15. The company has a market cap of $1.21 billion, a PE ratio of -10.92 and a beta of 0.91. The company has a 50-day moving average of $20.35 and a 200-day moving average of $23.74.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its earnings results on Tuesday, August 4th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.01). PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The firm had revenue of $94.50 million during the quarter, compared to analysts’ expectations of $92.77 million. During the same quarter in the prior year, the company earned ($0.35) EPS. The business’s revenue for the quarter was up 19.3% on a year-over-year basis. As a group, analysts anticipate that PROCEPT BioRobotics Corporation will post -1.67 earnings per share for the current year.

Insider Transactions at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, CEO Larry L. Wood bought 23,900 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was purchased at an average cost of $20.85 per share, with a total value of $498,315.00. Following the transaction, the chief executive officer directly owned 23,900 shares in the company, valued at $498,315. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders sold 1,000 shares of company stock valued at $28,480. 4.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC grew its holdings in PROCEPT BioRobotics by 7.3% during the first quarter. AQR Capital Management LLC now owns 18,892 shares of the company’s stock valued at $1,101,000 after purchasing an additional 1,286 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of PROCEPT BioRobotics by 9.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 153,158 shares of the company’s stock worth $8,923,000 after purchasing an additional 13,767 shares during the period. Intech Investment Management LLC raised its position in shares of PROCEPT BioRobotics by 54.4% in the first quarter. Intech Investment Management LLC now owns 28,389 shares of the company’s stock worth $1,654,000 after buying an additional 10,002 shares in the last quarter. Prudential Financial Inc. boosted its stake in PROCEPT BioRobotics by 100.4% during the second quarter. Prudential Financial Inc. now owns 6,815 shares of the company’s stock valued at $393,000 after buying an additional 3,415 shares during the period. Finally, State Street Corp raised its stake in PROCEPT BioRobotics by 6.9% in the second quarter. State Street Corp now owns 1,269,110 shares of the company’s stock valued at $73,101,000 after purchasing an additional 81,849 shares in the last quarter. 89.46% of the stock is owned by institutional investors.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.